Furthermore, ertugliflozin was associated with a preservation of eGFR and a consistent decrease in the urinary albumin/creatinine ratio (UACR), which was particularly beneficial in patients with macroalbuminuria and high/very high-risk CKD. Here, ALB is linked to chronic kidney disease.